IP Library Granted Patent US 8,784,796
Granted Patent B2
US 8,784,796 · App. 13/940,579 · Granted Jul 22, 2014

Vaccine immunotherapy for treating hepatocellular cancer in immune suppressed patients

Inventor: John W. Hadden (Cold Spring Harbor, NY)
Assignee: IRX Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,784,796
App. No.
13/940,579
Granted
Jul 22, 2014
Kind
B2
Abstract

A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.

Claims (10)

1. A method for treating hepatocellular cancer in a patient, the method comprising: administering to the patient having hepatocellular cancer an effective amount of a natural cytokine mixture comprising the cytokines IL-1beta, IL-2, IL-6, IL-8, IFN-gamma, and TNF-alpha.

2. The method of claim 1 , wherein the natural cytokine mixture is administered to the patient perilymphatically.

3. The method of claim 1 , wherein the method further comprises:

administering to the patient an effective amount of cyclophosphamide.

4. The method of claim 1 , wherein the method further comprises:

administering to the patient an effective amount of cyclophosphamide, and

administering to the patient an effective amount of a nonsteroidal anti-inflammatory drug (NSAID).

5. The method of claim 1 , wherein the method further comprises:

administering to the patient an effective amount of at least one exogenous tumor antigen.

6. The method of claim 1 , wherein the natural cytokine mixture further comprises GM-CSF and G-CSF.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2019
From: IRX THERAPEUTICS, INC.
To: BROOKLYN IMMUNOTHERAPEUTICS LLC
Reel/Frame 048424/0096 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2013
From: HADDEN, JOHN W.
To: IRX THERAPEUTICS, INC.
Reel/Frame 031229/0292 →
Continuity (5)
Continuation 11582063 · Oct 16, 2006
Division 10430506 · May 5, 2003
Continuation 10015123 · Oct 26, 2001
Provisional Application 60243912 · Oct 27, 2000
Related Publication 20140010780A1 · Jan 9, 2014